Literature DB >> 28361209

Correlation between clinical symptoms and striatal DAT uptake in patients with DLB.

Soichiro Shimizu1, Disuke Hirose2, Nayuta Namioka2, Hidekazu Kanetaka2, Kentaro Hirao2, Hirokuni Hatanaka2, Naoto Takenoshita2, Yoshitsugu Kaneko2, Yusuke Ogawa2, Takahiko Umahara2, Hirofumi Sakurai2, Haruo Hanyu2.   

Abstract

OBJECTIVE: It is widely known that there is low striatal 123I-FP-CIT dopamine transporter-single photon emission tomography (DAT-SPECT) uptake in patients with dementia with Lewy bodies (DLB). We assessed the correlation between symptom and regional low DAT uptake in the striatum.
METHODS: Patients with Alzheimer's disease (AD) (n = 95) and patients with DLB (n = 133) who underwent DAT-SPECT were enrolled. We examined the correlation between symptoms [cognitive function decline, fluctuations, visual hallucinations, parkinsonism, and REM sleep behavior disorder (RBD)] and regional striatal DAT uptake in the patients with DLB.
RESULTS: When comparing the DLB patients with or without fluctuations, visual hallucinations, or RBD, there were no significant differences in DAT uptake in any regions of the striatum. DLB patients with parkinsonism had significantly lower DAT uptake in entire striatum, entire putamen, and anterior putamen compared to DLB patients without parkinsonism. Moreover, there was weak but significant correlation between severity of parkinsonism and DAT uptake in entire regions of the striatum in patients with DLB. There was no significant correlation between cognitive function and DAT uptake in any regions of the striatum in patients with DLB.
CONCLUSIONS: In patients with DLB, only parkinsonism is associated with a reduction in striatal DAT uptake.

Entities:  

Keywords:  123I-FP-CIT; Alzheimer’s disease; DAT scan; Dementia with Lewy bodies; Parkinsonism

Mesh:

Substances:

Year:  2017        PMID: 28361209     DOI: 10.1007/s12149-017-1166-3

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  5 in total

Review 1.  Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2017-12-08       Impact factor: 3.575

Review 2.  Diagnostic imaging of dementia with Lewy bodies, frontotemporal lobar degeneration, and normal pressure hydrocephalus.

Authors:  Kazunari Ishii
Journal:  Jpn J Radiol       Date:  2019-09-23       Impact factor: 2.374

3.  Biomarker Use for Dementia With Lewy Body Diagnosis: Survey of US Experts.

Authors:  Melissa J Armstrong; David J Irwin; James B Leverenz; Noheli Gamez; Angela Taylor; James E Galvin
Journal:  Alzheimer Dis Assoc Disord       Date:  2021 Jan-Mar 01       Impact factor: 2.357

Review 4.  The Pharmacology of Visual Hallucinations in Synucleinopathies.

Authors:  Mirella Russo; Claudia Carrarini; Fedele Dono; Marianna Gabriella Rispoli; Martina Di Pietro; Vincenzo Di Stefano; Laura Ferri; Laura Bonanni; Stefano Luca Sensi; Marco Onofrj
Journal:  Front Pharmacol       Date:  2019-12-09       Impact factor: 5.810

5.  β-Amyloid PET and 123I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia.

Authors:  Qin Chen; Val J Lowe; Bradley F Boeve; Scott A Przybelski; Toji Miyagawa; Matthew L Senjem; Clifford R Jack; Timothy G Lesnick; Walter K Kremers; Julie A Fields; Hoon-Ki Min; Christopher G Schwarz; Jeffrey L Gunter; Jonathan Graff-Radford; Rodolfo Savica; David S Knopman; David Jones; Tanis J Ferman; Neill R Graff-Radford; Ronald C Petersen; Kejal Kantarci
Journal:  Neurology       Date:  2021-01-06       Impact factor: 9.910

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.